AKEBIA THERAPEUTICS, INC. Cost of Revenue
AKEBIA THERAPEUTICS, INC. (AKBA) reported Cost of Revenue of $10.42 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Cost of Sales
us-gaap:CostOfRevenue · last filed 2026-08-05
- AKEBIA THERAPEUTICS, INC. cost of revenue for the quarter ending 2026-06-30 was $10.42M, a 5.09% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. cost of revenue for the quarter ending 2026-03-31 was $12.29M, a 61.18% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. cost of revenue for the quarter ending 2025-12-31 was $12.54M, a 38.45% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. cost of revenue for the quarter ending 2025-09-30 was $9.38M, a 33.74% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. cost of revenue for fiscal 2025 was $39.46M, a 37.54% decline from fiscal 2024.
- AKEBIA THERAPEUTICS, INC. cost of revenue for fiscal 2024 was $63.18M, a 14.80% decline from fiscal 2023.
- AKEBIA THERAPEUTICS, INC. cost of revenue for fiscal 2023 was $74.15M, a 13.34% decline from fiscal 2022.
- AKEBIA THERAPEUTICS, INC. cost of revenue for fiscal 2022 was $85.57M, a 43.21% decline from fiscal 2021.
| Period end | Cost of Revenue 3 month | Cost of Revenue 3 month as first filed | Cost of Revenue 6 month | Cost of Revenue 6 month as first filed | Cost of Revenue 9 month | Cost of Revenue 9 month as first filed | Cost of Revenue 12 month | Cost of Revenue 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $10.42M 10-Q · filed 2026-08-05 | $22.71M 10-Q · filed 2026-08-05 | $35.25M derived: sum of 3 quarters · filed 2026-08-05 | $44.63M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $12.29M 10-Q · filed 2026-05-07 | $24.82M derived: sum of 2 quarters · filed 2026-05-07 | $34.21M derived: sum of 3 quarters · filed 2026-05-07 | $44.13M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $12.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $21.92M derived: sum of 2 quarters · filed 2026-02-26 | $31.84M derived: sum of 3 quarters · filed 2026-08-05 | $39.46M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $9.38M 10-Q · filed 2025-11-10 | $19.30M derived: sum of 2 quarters · filed 2026-08-05 | $26.93M 10-Q · filed 2025-11-10 | $47.29M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $9.92M 10-Q · filed 2026-08-05 | $17.54M 10-Q · filed 2026-08-05 | $37.91M derived: sum of 3 quarters · filed 2026-08-05 | $52.07M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $7.63M 10-Q · filed 2026-05-07 | $27.99M derived: sum of 2 quarters · filed 2026-05-07 | $42.15M derived: sum of 3 quarters · filed 2026-05-07 | $59.20M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $20.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $34.53M derived: sum of 2 quarters · filed 2026-02-26 | $51.57M derived: sum of 3 quarters · filed 2026-02-26 | $63.18M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $14.16M 10-Q · filed 2025-11-10 | $31.21M derived: sum of 2 quarters · filed 2025-11-10 | $42.81M 10-Q · filed 2025-11-10 | $61.48M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-30 | $17.05M 10-Q · filed 2025-08-07 | $28.65M 10-Q · filed 2025-08-07 | $47.32M derived: sum of 3 quarters · filed 2026-02-26 | $65.33M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-03-31 | $11.61M 10-Q · filed 2025-05-08 | $30.27M derived: sum of 2 quarters · filed 2026-02-26 | $48.28M derived: sum of 3 quarters · filed 2026-02-26 | $65.56M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2023-12-31 | $18.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $36.67M derived: sum of 2 quarters · filed 2026-02-26 | $53.96M derived: sum of 3 quarters · filed 2026-02-26 | $74.15M 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | $18.01M 10-Q · filed 2024-11-07 | $35.29M derived: sum of 2 quarters · filed 2024-11-07 | $55.48M 10-Q · filed 2024-11-07 | $52.05M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | $17.28M 10-Q · filed 2024-08-08 | $37.47M 10-Q · filed 2024-08-08 | $34.04M derived: sum of 3 quarters · filed 2024-08-08 | $72.33M derived: sum of 4 quarters · filed 2024-08-08 | ||||
| 2023-03-31 | $20.19M 10-Q · filed 2024-05-09 | $19.48M 10-Q · filed 2023-05-08 | $16.76M derived: sum of 2 quarters · filed 2024-05-09 | $55.04M derived: sum of 3 quarters · filed 2024-05-09 | $73.64M derived: sum of 4 quarters · filed 2024-05-09 | |||
| 2022-12-31 | -$3.43M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $34.85M derived: sum of 2 quarters · filed 2024-03-14 | $53.45M derived: sum of 3 quarters · filed 2024-03-14 | $85.57M 10-K · filed 2024-03-14 | $84.80M 10-K · filed 2023-03-10 | |||
| 2022-09-30 | $38.28M 10-Q · filed 2023-11-08 | $37.95M 10-Q · filed 2022-11-03 | $56.88M derived: sum of 2 quarters · filed 2023-11-08 | $89.00M 10-Q · filed 2023-11-08 | $87.89M 10-Q · filed 2022-11-03 | $135.85M derived: sum of 4 quarters · filed 2023-11-08 | ||
| 2022-06-30 | $18.60M 10-Q · filed 2023-08-28 | $50.72M 10-Q · filed 2023-08-28 | $49.94M 10-Q · filed 2022-08-04 | $97.57M derived: sum of 3 quarters · filed 2023-08-28 | $113.52M derived: sum of 4 quarters · filed 2023-08-28 | |||
| 2022-03-31 | $31.34M 10-Q · filed 2023-05-08 | $78.97M derived: sum of 2 quarters · filed 2023-08-28 | $94.92M derived: sum of 3 quarters · filed 2023-08-28 | $147.41M derived: sum of 4 quarters · filed 2023-08-28 | ||||
| 2021-12-31 | $47.63M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-08-28 | $63.57M derived: sum of 2 quarters · filed 2023-08-28 | $116.07M derived: sum of 3 quarters · filed 2023-08-28 | $150.67M 10-K/A · filed 2023-08-28 | $153.39M 10-K · filed 2022-03-01 | |||
| 2021-09-30 | $15.94M 10-Q · filed 2022-11-03 | $68.44M derived: sum of 2 quarters · filed 2022-11-03 | $103.04M 10-Q · filed 2022-11-03 | $166.28M derived: sum of 4 quarters · filed 2022-11-03 | ||||
| 2021-06-30 | $52.49M 10-Q · filed 2022-08-04 | $87.10M 10-Q · filed 2022-08-04 | $150.34M derived: sum of 3 quarters · filed 2022-08-04 | $180.68M derived: sum of 4 quarters · filed 2022-08-04 | ||||
| 2021-03-31 | $34.61M 10-Q · filed 2022-05-09 | $97.84M derived: sum of 2 quarters · filed 2022-05-09 | $128.19M derived: sum of 3 quarters · filed 2022-05-09 | $302.80M derived: sum of 4 quarters · filed 2022-05-09 | ||||
| 2020-12-31 | $63.23M 10-K · filed 2021-02-25 | $93.58M derived: sum of 2 quarters · filed 2021-11-04 | $268.19M derived: sum of 3 quarters · filed 2021-11-04 | $296.48M 10-K/A · filed 2023-08-28 | $295.91M 10-K · filed 2021-02-25 | |||
| 2020-09-30 | $30.34M 10-Q · filed 2021-11-04 | $204.96M derived: sum of 2 quarters · filed 2021-11-04 | $232.67M 10-Q · filed 2021-11-04 | $270.82M derived: sum of 4 quarters · filed 2021-11-04 | ||||
| 2020-06-30 | $174.62M 10-Q · filed 2021-08-05 | $202.33M 10-Q · filed 2021-08-05 | $240.48M derived: sum of 3 quarters · filed 2021-08-05 | $278.74M derived: sum of 4 quarters · filed 2021-08-05 | ||||
| 2020-03-31 | $27.71M 10-Q · filed 2021-05-10 | $65.86M derived: sum of 2 quarters · filed 2021-05-10 | $104.12M derived: sum of 3 quarters · filed 2021-05-10 | $141.79M derived: sum of 4 quarters · filed 2021-05-10 | ||||
| 2019-12-31 | $38.15M 10-K · filed 2021-02-25 | $76.41M derived: sum of 2 quarters · filed 2021-02-25 | $114.08M derived: sum of 3 quarters · filed 2021-02-25 | $145.34M 10-K · filed 2022-03-01 | ||||
| 2019-09-30 | $38.26M 10-K · filed 2021-02-25 | $75.93M derived: sum of 2 quarters · filed 2021-02-25 | $107.19M 10-Q · filed 2020-11-05 | $114.96M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-06-30 | $37.67M 10-K · filed 2021-02-25 | $68.93M 10-Q · filed 2020-08-10 | $76.69M derived: sum of 3 quarters · filed 2021-02-25 | |||||
| 2019-03-31 | $31.26M 10-K · filed 2021-02-25 | $39.02M derived: sum of 2 quarters · filed 2021-02-25 | ||||||
| 2018-12-31 | $7.77M 10-K · filed 2020-03-12 | $7.77M 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |